Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer

Sponsor
Mohammed Mahmood Mohammed
Study ID
NCT06843954
Phase
PHASE4
Status
Completed

Conditions

  • Colo-rectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    bevacizumab (7.5mg/kg every 21 days) for minimum of 3 cycles

Study Details

This study will be a prospective one conducted within a time frame between September 2022 and April 2023. One hundred adult patients already diagnosed with CRC and received bevacizumab and chemotherapy consisting of fluorouracil and leucovorin or capecitabine in combination with either oxaliplatin (FOLFOX or XELOX) or irinotecan (FOLFIRI or XELIRI). Three to six cycles will be given, and to explore the response to treatment, the Response Evaluation Criteria in Solid Tumors (RECIST) will be used to assess the response.

Key Dates

First listed
Feb 25, 2025
Start date
Sep 1, 2022
Status verified
Feb 2025
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023

Study Design

Enrollment
157 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab Group
    Patients diagnosed with mCRC and received bevacizumab (7.5mg/kg every 21 day) in association with combined regimen standard chemotherapy (FOLFOX, FOLFIRI, XELOX)

Primary Outcome Measure

Complete response rate (CR) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]

Related Studies